July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study
Author Affiliations & Notes
  • Julia Sein
    Retina, John Hopkins University , Baltimore, Maryland, United States
  • Ahmad Mansour
    American University of Beirut , Beirut , Lebanon
    Ophthalmology , Rafic Hariri University Hospital, Beirut , Lebanon
  • Roberto E E Foster
    Ophthalmology , University of Cincinnati , Cincinnati , Ohio, United States
  • Roberto Gallego-Pinazo
    Ophthalmology , University and Polytechnic Hospital La Fe, Valencia , Spain
  • Marilita M Moschos
    University of Athens, Athens, Greece
  • Robert Sisk
    Ophthalmology , University of Cincinnati , Cincinnati , Ohio, United States
  • Jay Chhablani
    Ophthalmology , LV Prasad Eye Institute, Hyberabad, India
  • Duangnate Rojanaporn
    Ophthalmology , Mahidol University Faculty of Medicine, Bangkok, Thailand
  • Tharikarn Sujirakul
    Ophthalmology , Mahidol University Faculty of Medicine, Bangkok, Thailand
  • Luiz Lima
    Federal University of Sao Paulo , San Paulo , Brazil
  • Lihteh Wu
    Asociados de Macula Vitreo y Retina de Costa Rica, San Jose, Costa Rica
  • Abdulrazzak Charbaji
    Statistics and Research Methodology , Lebanese American University, Beirut, Lebanon
  • Hana Mansour
    American University of Beirut , Beirut , Lebanon
  • Yogin Patel
    Ophthalmology , University of Cincinnati , Cincinnati , Ohio, United States
  • Sankeert Gangakhedkar
    Ophthalmology , LV Prasad Eye Institute, Hyberabad, India
  • J Fernando Arevalo
    Retina, John Hopkins University , Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Julia Sein, None; Ahmad Mansour, None; Roberto E Foster, None; Roberto Gallego-Pinazo, None; Marilita Moschos, None; Robert Sisk, None; Jay Chhablani, None; Duangnate Rojanaporn, None; Tharikarn Sujirakul, None; Luiz Lima, None; Lihteh Wu, None; Abdulrazzak Charbaji, None; Hana Mansour, None; Yogin Patel, None; Sankeert Gangakhedkar, None; J Fernando Arevalo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4284. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Julia Sein, Ahmad Mansour, Roberto E E Foster, Roberto Gallego-Pinazo, Marilita M Moschos, Robert Sisk, Jay Chhablani, Duangnate Rojanaporn, Tharikarn Sujirakul, Luiz Lima, Lihteh Wu, Abdulrazzak Charbaji, Hana Mansour, Yogin Patel, Sankeert Gangakhedkar, J Fernando Arevalo; Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4284.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There is no established therapy for exudative-hemorrhagic complications in primary retinal arteriolar macroaneurysm (RAM). The aim of the study is to further delineate the risks and benefits of anti-VEGF therapy in eyes with RAM and visual loss.

Methods : Retrospective multicenter interventional study of anti-vascular endothelial growth factor (anti-VEGF) in symptomatic RAM. Central macular thickness (CMT) in microns and best corrected visual acuity (BCVA) in logMar were correlated with RAM size and distance to the macula. Statistical analyses were performed using paired comparisons and Pearson correlation.

Results : 32 eyes (32 patients) were treated with a mean of 2.7 injections over mean follow-up of 16.6 months. Initial BCVA correlated with RAM size and distance to the macula (p=0.02). Ranibizumab was used in 14 patients, bevacizumab in 16 patients, and aflibercept in 2 patients (in combination with bevacizumab in 1 patient, and with both ranibizumab and bevacizumab in 1 patient). CMT decreased by 131,180, 211 at 1, 2, 3 months after the first injection (p<0.001). BCVA improved by 0.47 and 0.38 at 2 and 3 months (p=0.005). Anti-VEGF response correlated with RAM size (p=0.04) and distance to the macula (p=0.009). No eye had retinal bleeding or re-bleeding while under anti-VEGF therapy. Most RAM closed (functional closure in 31 of 32 eyes) after a few injections.

Conclusions : Symptomatic RAM can be treated successfully with anti-VEGF injections leading to decrease in macular edema.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×